The Swiss drug company says it is temporarily suspending enrollment in a midstage clinical trial to test its anemia drug Cera because of safety concerns over an "imbalance" of death across the four arms of the study. The announcement is likely to raise concern among federal regulators over the safety of all EPO drugs, including Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit.

Full Story:

Related Summaries